WUHN
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2022 Q3 | -0.13 | $4,573 | $189,507 |
| 2022 Q2 | -0.01 | $0 | -$214,236 |